Company
Haemonetics
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
8
510(k), De Novo and PMA
Device trials
5
As lead sponsor, any status
Adverse event reports
2
Received Nov 1, 2025 to Nov 19, 2026
Recall records
48
One per recalled product
Haemonetics is on our public-company list (ticker HAE). Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
HAE
NYSE · HAEMONETICS CORP
Public float
$2.23B
Value of shares held by non-insiders on Sep 27, 2025
Revenue
$1.33B
Fiscal year ending Mar 28, 2026
Net income
$97.3M
Fiscal year ending Mar 28, 2026
R&D spending
$59.8M
Fiscal year ending Mar 28, 2026
Cash
$261M
As of Sep 26, 2026
Long-term debt
$1.14B
As of Sep 26, 2026
Shares outstanding
45.5M
As of Oct 30, 2026
Capital raised as a public company
Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.
| Year | IPO | Stock sold | Long-term debt | Convertible debt |
|---|---|---|---|---|
| 2025 | – | – | – | $700M |
| 2021 | – | – | – | $500M |
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
K251024 · Decided Apr 30, 2025 · 28 days after receipt
Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA) · Laboratory Medicine & Pathology
K243858 · Decided Jan 15, 2025 · 30 days after receipt
Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA) · Laboratory Medicine & Pathology
K232018 · Decided Mar 29, 2024 · 266 days after receipt
Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- The AMBULATE EXPAND Trial: VASCADE MVP XL for Femoral Venous Access Sites, 16-17F ODPivotal-lookingCompleted
NCT06615154 · 85 participants · Start Feb 28, 2025 · Primary completion Aug 18, 2025
Device: VASCADE MVP XL (800-1014XL) · For: Surgical Wound; Vascular Access
NCT02476851 · 62 participants · Start Jun 2015 · Primary completion Jul 2015
Device: POLFA (Needle Assembly); Kawasumi (Needle Assembly) · For: Transmission, Blood, Recipient/Donor
Sites: Braintree, Massachusetts; Cincinnati, Ohio; Norfolk, Virginia
- IMPACT (Improving Plasma Collection) Clinical TrialPivotal-lookingCompleted
NCT04320823 · 3,443 participants · Start Jan 6, 2020 · Primary completion Mar 27, 2020
Device: Updated Plasma Collection Feature; Current Plasma Collection Approach · For: Apheresis Related Hypotension
Sites: Wichita, Kansas; Charlotte, North Carolina; Spokane, Washington
2 more trials with a free account
Reports received
2
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
0.0% of reports
Injury reports
0
0.0% of reports
Death reports
2
100% of reports
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 6 | 4 | 0 |
| Jan 24 | 0 | 0 | 2 | 0 |
| Feb 24 | 0 | 0 | 1 | 0 |
| Mar 24 | 0 | 0 | 3 | 0 |
| Apr 24 | 0 | 0 | 1 | 0 |
| May 24 | 0 | 0 | 1 | 0 |
| Jun 24 | 1 | 0 | 1 | 0 |
| Jul 24 | 1 | 0 | 1 | 0 |
| Aug 24 | 2 | 0 | 3 | 0 |
| Sep 24 | 0 | 0 | 1 | 0 |
| Oct 24 | 1 | 0 | 4 | 0 |
| Nov 24 | 0 | 0 | 3 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 2 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 2 | 0 | 1 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 1 | 0 | 0 |
| Jun 25 | 0 | 1 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 1 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 1 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1310-2022 · Started Apr 26, 2022
Reason given: Due to a shift in the citrated blood reference range for a normal population, the ranges stated in the IFU are changing. If the clinician relies solely on affected results in comparison to the normal donor reference range, it could lead to misdiagnosis and incorrect treatment or failure to treat.
Cause as FDA categorized it: Other · Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA)
Z-1298-2022 · Started Apr 19, 2022
Reason given: When the TEG 5000 Analyzer including TEG Analytical Software is used with PlateletMapping (ADP or AA) Assays and TEG Mangement Software, incorrect values of the PlateletMapping ADP or AA % Inhibition and % Aggretagion may be displayed on TEG Manager for the affected assays.
Cause as FDA categorized it: Software design · Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA)
Z-1617-2020 · Started Feb 19, 2020
Reason given: Software defect in TEG Manager impacts the displayed alert for out of range test results. Due to this defect, reference range values received from TEG 5000 and displayed on the TEG Manager test result screen are rounded to the nearest whole number and lead to TEG Manager displaying an out of range alert when the test...
Cause as FDA categorized it: Software design · Device type: System, Multipurpose For In Vitro Coagulation Studies (JPA)
45 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.